BARHL1

Across TCGA pan-cancer cohorts, BARHL1 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of BARHL1’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where BARHL1 RNA is repressed in tumor relative to normal tissue. In most cancer types BARHL1 is over-expressed in tumor, although a few such as THCA and COAD show the opposite, repressed pattern.

THCA, STAD, and COAD are the cancer types where BARHL1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BARHL1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Female	II,III,IV	−0.026	.005	4	view →
STAD	Male	II,III,IV	+0.071	.025	2	view →
COAD	All	II,III,IV	−0.018	.024	1	view →
LIHC	All	All	+0.004	.046	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

BARHL1–THCA

Open the THCA breakdown →